What's new? Log in Free sign up

Bicycle Therapeutics (BCYC)

Company Profile

Company profile

Ticker

BCYC

Exchange

Website

www.bicycletherapeutics.com

CEO

Dr. Kevin Lee M.B.A., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

BICYCLE THERAPEUTICS Ltd

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

BCYC stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$25.25

Low target

$17.00

High target

$33.00

Market Outperform

HC Wainwright & Co.

B. Riley Securities

Latest filings (excl ownership)

View all

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Quarterly report

31 Oct 24

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Termination of a Material Definitive Agreement

Prospectus with selling stockholder info

$555.50 mm in equity, sold $555.50 mm, 19 investors

Entry into a Material Definitive Agreement

Latest ownership filings

View all

BAKER BROS. ADVISORS LP

RA CAPITAL MANAGEMENT, L.P.

Paradigm Biocapital Advisors LP

Jefferies Financial Group Inc.

Travis Alvin Thompson

Notice of proposed sale of securities

Michael Charles Ferguson Hannay

Michael Skynner

Financial summary

Financial statements Chart BCYC financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	891.41 mm	891.41 mm	891.41 mm	891.41 mm	891.41 mm	891.41 mm
Cash burn (monthly)	(no burn)	(no burn)	21.28 mm	16.72 mm	300.00 k	10.01 mm
Cash used (since last report)	n/a	n/a	59.29 mm	46.57 mm	835.80 k	27.88 mm
Cash remaining	n/a	n/a	832.12 mm	844.84 mm	890.57 mm	863.53 mm
Runway (months of cash)	n/a	n/a	39.1	50.5	2968.6	86.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

BCYC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	109	111	-1.8%
Opened positions	18	26	-30.8%
Closed positions	20	12	+66.7%
Increased positions	34	35	-2.9%
Reduced positions	32	25	+28.0%

13F shares	Current	Prev Q	Change
Total value	820.26 bn	741.37 bn	+10.6%
Total shares	44.81 mm	44.31 mm	+1.1%
Total puts	24.60 k	12.40 k	+98.4%
Total calls	39.60 k	3.40 k	+1064.7%
Total put/call ratio	0.6	3.6	-83.0%

Largest owners	Shares	Value	Change
Baker Bros. Advisors	9.40 mm	$212.72 bn	0.0%
Deep Track Capital	3.55 mm	$80.29 bn	+1.6%
FCPM Iii Services B.V.	2.34 mm	$52.95 bn	+10.2%
Ra Capital Management	2.25 mm	$50.99 bn	0.0%
Armistice Capital	1.96 mm	$44.26 bn	-0.8%
Westfield Capital Management	1.85 mm	$41.89 bn	+21.5%
T. Rowe Price	1.72 mm	$38.97 mm	+115.7%
SVLSF V	1.56 mm	$54.41 mm	0.0%
GSK GSK	1.53 mm	$39.40 mm	0.0%
Tybourne Capital Management	1.39 mm	$31.56 bn	-7.6%

Largest transactions	Shares	Bought/sold	Change
Fairmount Funds Management	123.54 k	-945.66 k	-88.4%
T. Rowe Price	1.72 mm	+923.54 k	+115.7%
Point72 Asset Management	899.80 k	+841.30 k	+1438.1%
Avoro Capital Advisors	0.00	-700.00 k	EXIT
Woodline Partners	0.00	-586.62 k	EXIT
Logos Global Management	500.00 k	+500.00 k	NEW
PFG Principal Financial	443.14 k	+443.14 k	NEW
BLK BlackRock	419.76 k	+419.76 k	NEW
First Light Asset Management	967.01 k	-417.76 k	-30.2%
BLK BlackRock	0.00	-402.22 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BCYC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	15.3418	457,631	7.02 mm	9,995,274
16 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	15.3418	42,369	650.02 k	914,083
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.804	566,814	7.82 mm	9,537,643
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.804	52,656	726.86 k	871,714
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.7242	244,587	3.36 mm	8,970,829
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.7242	22,722	311.84 k	819,058
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.6288	59,995	817.66 k	8,726,242
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.6288	5,573	75.95 k	796,336
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.4979	30,241	408.19 k	8,666,247
13 Dec 24	Baker Bros. Advisors	American Depositary Shares	Buy	Acquire P	Yes	No	13.4979	2,809	37.92 k	790,763

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday

JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $26

JMP Securities analyst Reni Benjamin maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and lowers the price target from $32 to $26.

Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views

HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $33

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press releases

From Benzinga Pro

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on December 2, 2024, the Compensation Committee of the company's Board of Directors granted to thirteen new employees inducement awards consisting of

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.